Send to printer »

Insight & Intelligence™ : Jul 29, 2013

Top 15 Pharma Companies of 2013

We've given last year's Top 10 Pharma Firms list an update.

Last year, we gave you the top 10 pharma firms; this year, we turn the volume up to 15. Following is a list of 15 pharmaceutical companies, ranked by their market capitalization for the latest date that they furnished a figure for their numbers of outstanding shares and a year-ago figure for the same. 

Pharmas, as with the biotechs listed in this space last week, benefited from the stock market surge that lifted share prices by mostly double-digit percentages over the past year. However, none of the 15 top pharma companies listed here had been able to double their market cap year-over-year; by contrast, five biotechs saw their market cap more than double over a 12-month period. Investors rewarded pharmas that performed well, though not as handsomely as biotechs that delivered.

Another factor in the lower market cap increases of pharmas compared with biotechs was the fact several of the companies were in the middle of restructuring efforts announced in earlier years, mostly related to loss of patent exclusivity on older blockbuster drugs. As reflected by GEN’s recent list of Top 15 Job-Cutting Companies of 2013 (So Far), pharmas carried out more job-cutting in the first half of 2013 compared with 2012.

The past year also saw some flux among the companies listed. Of this year’s top 15 (the 2012 GEN List of top pharmas included only 10 companies), two pharmas climbed up the list (Novartis and Sanofi); four slipped a notch or more (Roche, Merck & Co., GlaxoSmithKline, and AstraZeneca); three companies were ranked the same as last year; five were ranked for the first time (Bayer, Eli Lilly, Takeda, Astellas, and Daiichi Sankyo); and the remaining company (AbbVie) didn’t exist last year, rendering comparisons to 2012 moot.

#15. Daiichi Sankyo

2013 Market Cap: $12.876 billion (3/31: 704 million shares * price ¥1,815 on 3/29)1,2,3

2012 Market Cap: $10.701 billion (3/31: 704 million shares * price ¥1,508 on 3/30)1,2,3

% Change: 20.3%

Position on 2012 List: Not ranked

#14. Astellas

2013 Market Cap: $23.888 billion (3/31: 467.965 million shares * price ¥5,060 on 3/29)1,2,3

2012 Market Cap: $16.050 billion (3/31: 467.965 million shares * price ¥3,400 on 3/30)1,2,3

% Change: 48.8%

Position on 2012 List: Not ranked

#13. Takeda

2013 Market Cap: $40.056 billion (3/31: 789.666 million shares * price ¥5,030 on 3/29)1,2,3

2012 Market Cap: $29.027 billion (3/31: 789.666 million shares * price ¥3,645 on 3/30)1,2,3

% Change: 38.0%

Position on 2012 List: Not ranked

#12. AstraZeneca

2013 Market Cap: $62.475 billion (3/31: 1.250 billion shares * price $49.98 on 3/28)2

2012 Market Cap: $56.680 billion (3/31: 1.274 billion shares * price $44.49 on 3/30)2

% Change: 10.2%

Position on 2012 List: #10

#11. Eli Lilly

2013 Market Cap: $64.687 billion (4/20: 1,126,561,464 shares * price $57.42 on 4/19)4

2012 Market Cap: $46.312 billion (4/20: 1,160,415,307 shares * price $39.91)

% Change: 39.7%

Position on 2012 List: Not ranked

#10. AbbVie

2013 Market Cap: $64.584 billion (3/31: 1,583,729,114 shares * price $40.78 on 3/28)2

2012 Market Cap: N/A5

% Change: N/A5

Position on 2012 List: N/A5

#9. Bristol-Myers Squibb

2013 Market Cap: $67.657 billion (3/31: 1,642,551,939 shares * price $41.19 on 3/28)2

2012 Market Cap: $57.007 billion (3/31: 1,689,084,439 shares * price $33.75 on 3/30)2

% Change: 18.7%

Position on 2012 List: #9

#8. Bayer

2013 Market Cap: $87.527 billion (3/31: €66.545 billion)1,6

2012 Market Cap: $57.365 billion (3/31: €43.613 billion)1,6

% Change: 52.6%

Position on 2012 List: Not ranked

#7. GlaxoSmithKline

2013 Market Cap: $112.511 billion (3/31: 4.834 billion shares * 1,538.50p [£15.385] on 3/29)1,7,8

2012 Market Cap: $104.852 billion (3/31: 4.963 billion shares * 1,396.50p [£13.965] on 3/30)1,7,8

% Change: 7.3%

Position on 2012 List: #6

#6. Merck & Co.

2013 Market Cap: $141.922 billion (4/30: 3,019,611,844 shares * price $47.00)

2012 Market Cap: $118.710 billion (4/29: 3,086,584,896 shares * price $38.46 on 4/27)9

% Change: 19.6%

Position on 2012 List: #4

#5. Sanofi

2013 Market Cap: $148.381 billion (5/10: 1,324,058,064 shares * price €85.130)1,10

2012 Market Cap: $98.322 billion (5/10: 1,342,007,588 shares * price €55.660)1,10

% Change: 50.9%

Position on 2012 List: #8

#4. Roche

2013 Market Cap: $166.477 billion (1/1: CHF 156.582 billion)1,11

2012 Market Cap: $144.778 billion (1/1: CHF 136.102 billion)1,11

% Change: 15.0%

Position on 2012 List: #3

#3. Novartis

2013 Market Cap: $173.4 billion (6/30: 2,447,415,490 shares * price CHF 67.10)1,12

2012 Market Cap: $133.9 billion (6/30: 2,417,862,200 shares * price CHF 52.90)1,12

% Change: 29.5%

Position on 2012 List: #5

#2. Pfizer

2013 Market Cap: $203.717 billion (5/6: 7,093,223,330 shares * price $28.72)

2012 Market Cap: $168.109 million (5/7: 7,488,136,070 shares * price $22.45)

% Change: 21.2%

Position on 2012 List: #2

#1. Johnson & Johnson

2013 Market Cap: $248.393 billion (6/30: 2.8930 billion shares * price $85.86 on 6/28)13,14

2012 Market Cap: $189.046 billion (6/30: 2.7982 billion shares * price $67.56 on 6/29)13,14

% Change: 31.4%

Position on 2012 List: #1